Design Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Design Therapeutics Stock-Based Compensation Growth & History (DSGN)
Design Therapeutics's stock-based compensation was $14.5M for fiscal 2025.
View full Design Therapeutics company overviewDesign Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.5M | $1.5M | +11.30% |
| 2024 | 2024-12-31 | $13.1M | −$16,000 | −0.12% |
| 2023 | 2023-12-31 | $13.1M | $2.2M | +19.80% |
| 2022 | 2022-12-31 | $10.9M | $6.2M | +132.99% |
| 2021 | 2021-12-31 | $4.7M | $4.2M | +942.00% |
| 2020 | 2020-12-31 | $450,000 | — | — |
Design Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.9M | −$118,000 | −2.96% |
| Q1 2026 | 2026-03-31 | $3.9M | $385,000 | +10.88% |
| Q4 2025 | 2025-12-31 | $3.4M | −$36,000 | −1.04% |
| Q3 2025 | 2025-09-30 | $3.6M | $472,000 | +15.14% |
| Q2 2025 | 2025-06-30 | $4.0M | $686,000 | +20.79% |
| Q1 2025 | 2025-03-31 | $3.5M | $355,000 | +11.15% |
| Q4 2024 | 2024-12-31 | $3.5M | $747,000 | +27.42% |
| Q3 2024 | 2024-09-30 | $3.1M | −$101,000 | −3.14% |
| Q2 2024 | 2024-06-30 | $3.3M | −$420,000 | −11.29% |
| Q1 2024 | 2024-03-31 | $3.2M | −$242,000 | −7.06% |
| Q4 2023 | 2023-12-31 | $2.7M | −$352,000 | −11.44% |
| Q3 2023 | 2023-09-30 | $3.2M | $347,000 | +12.08% |
| Q2 2023 | 2023-06-30 | $3.7M | $1.1M | +42.11% |
| Q1 2023 | 2023-03-31 | $3.4M | $1.1M | +45.17% |
| Q4 2022 | 2022-12-31 | $3.1M | $1.5M | +97.69% |
| Q3 2022 | 2022-09-30 | $2.9M | $1.6M | +131.05% |
| Q2 2022 | 2022-06-30 | $2.6M | $1.4M | +110.54% |
| Q1 2022 | 2022-03-31 | $2.4M | $1.7M | +264.76% |
| Q4 2021 | 2021-12-31 | $1.6M | $1.1M | +269.60% |
| Q3 2021 | 2021-09-30 | $1.2M | $1.2M | +8186.67% |
| Q2 2021 | 2021-06-30 | $1.2M | $1.2M | +12330.00% |
| Q1 2021 | 2021-03-31 | $647,000 | $643,000 | +16075.00% |
| Q4 2020 | 2020-12-31 | $421,000 | — | — |
| Q3 2020 | 2020-09-30 | $15,000 | — | — |
| Q2 2020 | 2020-06-30 | $10,000 | — | — |
| Q1 2020 | 2020-03-31 | $4,000 | — | — |
Design Therapeutics stock-based compensation trends
Over the last five fiscal years, Design Therapeutics's stock-based compensation increased from $450,000 to $14.5M, a change of $14.1M. The latest reported quarter, Q2 2026, shows $3.9M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Design Therapeutics source filings ↗